Skip to main content
CHITOGENX INC logo

CHITOGENX INC — Investor Relations & Filings

Ticker · CHGX ISIN · CA1699161032 CSE Professional, scientific and technical activities
Open in API
Filings indexed 160 across all filing types
Latest filing 2025-09-09 Regulatory Filings
Country CA Canada
Listing CSE CHGX

About CHITOGENX INC

https://www.chitogenx.com

ChitogenX Inc. is a clinical stage regenerative medicine company dedicated to developing novel therapeutic tissue repair technologies. Initially focused on orthopedic and sports medicine biologics, the company aims to enhance the natural healing of soft tissues. Its core development program centers on ORTHO-R, a platform technology currently being advanced for multiple indications. Recent expansion efforts include launching a development program for burn and skin repair applications, utilizing its expertise in regenerative biomaterials.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Canadian Form 51-102F3 Material Change Report filed on SEDAR+, announcing (1) a binding letter of intent for a reverse takeover (an M&A event), (2) a partial revocation of a cease trade order, and (3) a proposed private placement of debentures. It is a formal continuous disclosure filing under Canadian securities rules rather than just a pure earnings release, proxy, or standalone M&A announcement. No other specific category (e.g. TAR, CAP) perfectly covers the broad scope of a mandated Material Change Report, so it falls under the general Regulatory Filings (RNS) category as a catch-all for compliance documents.
2025-09-09 English
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a press release announcing that ChitogenX has entered into a binding letter of intent to pursue a reverse takeover (“RTO”) transaction with Oligo Medic, along with related financing and regulatory clearance. The central focus is on the proposed RTO (a merger/takeover structure) rather than simple earnings, dividends, board changes, or ESG reporting. This fits squarely under M&A Activity (Code: TAR).
2025-09-09 English
52-109FV2 - Certification of interim filings - CEO (F).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109 FV2 “Venture Issuer Basic Certificate” certifying the interim financial report and interim MD&A for the period ended October 31, 2024. It does not contain the financial statements or MD&A themselves (so it is not the interim report), nor does it announce publication or include a link (so it is not an RPA). It is a standalone regulatory certification form under Canadian NI 52-109, which does not fit any more specific category, so it falls into the fallback Regulatory Filings category (RNS).
2024-12-22 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a NI 52-109 Venture Issuer Basic Certificate certifying the interim filings (interim financial report and MD&A) for the period ended October 31, 2024. It is not the interim report itself (no financial statements or MD&A text) nor an announcement of report publication. There is no specific category for certification letters under Canadian securities rules, so this falls under the general “Regulatory Filings” (RNS) fallback category.
2024-12-22 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis for the three and nine-month periods ended October 31, 2024.” It provides management’s narrative overview, non-IFRS measures, business strategy, operational commentary, and forward-looking statements for an interim period. It is not the full financial statements or an earnings release, but the MD&A section, which aligns with the “Management Reports” category (Code: MDA).
2024-12-22 English
Interim financial statements/report – English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis for the three and nine-month periods ended October 31, 2024” and provides an in-depth MD&A on operations, performance, non-IFRS measures, business strategy, and outlook for the third quarter of fiscal 2025. It explicitly states it should be read with the unaudited interim condensed consolidated financial statements, but only the MD&A narrative is included. This matches our “Management Reports (MDA)” category—management’s detailed explanation of financial results, business trends, and outlook—rather than a brief earnings release or the full interim/quarterly financial report itself.
2024-12-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.